Altamira Therapeutics Ltd
NASDAQ:CYTO
Altamira Therapeutics Ltd
Pre-Tax Income
Altamira Therapeutics Ltd
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
Pre-Tax Income
-CHf7.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Novartis AG
SIX:NOVN
|
Pre-Tax Income
$12.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
Roche Holding AG
SIX:ROG
|
Pre-Tax Income
CHf14.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Pre-Tax Income
$130m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Altamira Therapeutics Ltd's Pre-Tax Income?
Pre-Tax Income
-7.3m
CHF
Based on the financial report for Dec 31, 2023, Altamira Therapeutics Ltd's Pre-Tax Income amounts to -7.3m CHF.
What is Altamira Therapeutics Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
8%
Over the last year, the Pre-Tax Income growth was 73%. The average annual Pre-Tax Income growth rates for Altamira Therapeutics Ltd have been 4% over the past three years , 8% over the past five years .